CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

COVID-19 PneumoniaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2678 WJ-MSCs Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Quality of Life and Long-term Outcomes in Patients With Pneumonia Associated With SARS-Cov2 Infection, Survivors of Intensive Care Units: a Prospective Multicenter Cohort Study

Patients suffering from pneumonia due to SARS-CoV-2 infection, after admission to the Intensive Care Unit (ICU), are susceptible to development of various functional sequelae, increased risk of chronic diseases, increased mortality rates and existence of relevant impacts on their quality of life in the months and years that follow the ICU admission. The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among patients recovered from SARS-COV-2 pneumonia, after discharge from the ICU, its determinants and predictors, in Portugal. It is a multicenter prospective cohort study of adult patients admitted at the ICU due to proven or suspected SARS-CoV-2 infection, included 90 days after discharge from the ICU. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. The secondary outcomes are all-cause mortality, rehospitalizations, return to work or study, the degree of dependence and functional capacity, symptoms of anxiety, depression and post-traumatic stress, level of physical activity and cognitive, renal and respiratory functions after ICU discharge. Investigators will collect data by means of structured telephone interviews, at a 12 months follow up period.

NCT04416464 Quality of Life Long-term Outcomes Coronavirus Infection Morality Rehospitalization Other: COVID-19 Pneumonia
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: The outcome will be assessed using the Portuguese version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).

Measure: Health-related quality of life.

Time: One-year (12 months) after ICU discharge.

Secondary Outcomes

Description: Length of stay at the ICU.

Measure: Length of stay at the ICU.

Time: The outcome will be assessed 3 months after ICU discharge (at the participant enrollment).

Description: Incidence of all-cause mortality.

Measure: Incidence of all-cause mortality

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: Rehospitalization.

Measure: Rehospitalization.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: Percentage of patients requiring oxygen therapy, non-invasive ventilation, or mechanical ventilation.

Measure: Percentage of long-term ventilatory support need.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: Percentage of patients requiring any kind of renal replacement therapy.

Measure: Percentage of renal replacement therapy need.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: The outcome will be assessed using the Hospital Anxiety and Depression Scale (anxiety and depression scores range from 0 to 21, with higher scores indicating worse symptoms).

Measure: Symptoms of anxiety and depression.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: The outcome will be assessed using the Lawton & Brody Instrumental Activities of Daily Living Scale, a score of instrumental activities of daily living (the score ranges from 0 to 8, with higher scores indicating less dependence).

Measure: Score of functional independence.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: The outcome will be assessed using the The Montreal Cognitive Assessment (MoCA). The score ranges from 0 to 30, in 8 domains, with higher scores indicating worse symptoms.

Measure: Score of cognitive function.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: Percentage of major cardiac events.

Measure: Percentage of major cardiac events.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: Score of Chronic obstructive pulmonary disease (COPD) assessed using the Portuguese version of the Clinical COPD Questionnaire (CCQ). The Clinical COPD, consisting of 10 items (each scored between 0 and 6), divided into three domains (symptoms, functional, mental). The total score is calculated by summing the scores of the individual items and dividing by 10 (the number of individual items) giving a total score between 0 and 6 with higher scores representing worse scenario.

Measure: Score of Chronic obstructive pulmonary disease (COPD)

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: The outcome will be assessed using the Impact Event Scale-Revised (the score ranges from 0 to 88, with higher scores indicating worse symptoms).

Measure: Symptoms of posttraumatic stress disorder

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: The outcome will be assessed using the Portuguese version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).

Measure: Utility score of health-related quality of life at 3, 6, and 9 months.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

Description: The outcome will be assessed using the visual analogue scale of the Portuguese version of the Euroqol-5D-3L questionnaire (EQ-VAS; score range from o to 100, with higher scores indicating better self-rated health).

Measure: Score of self-rated health.

Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.

No related HPO nodes (Using clinical trials)